Recently founded by a leading venture capital firm, this new firm is interested in investing in and establishing strategic partnerships with innovative medtech companies. The firm is looking for domestic and cross-border partnerships in terms of equity investment, license-in, distribution and others. The firm can invest anywhere from hundreds of thousands to 10MM USD, and is open to both leading and co-investing. The firm looks for opportunities globally.

The firm focuses on all classes of medical devices, including PMA, 510k and software enabled devices, all the way from in-development to commercialization stage. The firm is also interested in diagnostics/monitoring devices, PMA and 510k diagnostics technologies. The firm looks for truly innovative technologies. Interested indications include but are not limited to minimally invasive surgical devices, neurology, oncology, ophthalmic, dental, urology, GI and ENT.

The firm has no specific requirement for the company and its management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life-sciences focused venture capital firm currently making investments into US-based companies out of its fourth fund primarily makes equity investment into seed and early stage rounds ranging from $250,000 to $1 million initially and up to $2 million over the lifetime of the investment.  The firm could make as many as 3 new investments over the next 6-9 months.

The firm is looking for U.S. companies in sectors of Therapeutics, Diagnostics, Medical Devices, Life Science Tools and digital health. The firm is agnostic in terms of subsectors and indications within these areas and is also interested in orphan indications and wireless medical devices. The firm looks to invest in early-stage companies including pre-clinical stage companies with some supporting in-animal data, although it is not a requirement.

The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role as an investor and generally looks to take a board or board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An impact investment arm of a non-profit organization manages an evergreen fund and is interested in therapeutics, diagnostics or screening technology, medical devices, digital health or tech enabled services that align with the firm’s mission to advance the fight against cancer. The firm will invest in companies of all stages of development (excluding public companies), and looks for companies that are advancing science, reducing disparities, and promoting health care sustainability; though there is a preference for Seed and Series A stage companies. The firm’s typical check size ranges from $250K-$2 million per round and reserves additional funds for follow-on investments. The firm is currently looking to co-invest, and will consider global opportunities, but is currently investing mostly in the US.

While relatively agnostic to technology within therapeutics, medical devices, diagnostics and digital health, The firm will only invest in companies relevant to the indication of oncology.

The firm is looking to co-invest in private companies only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based firm is investing from its second fund and manages about $150M AUM. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital firm based in USA is currently investing out of their fourth fund. The firm looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor.

The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data.

The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring its investment to fund clinical trials and regulatory approval.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global venture capital and commercial development firm based in the USA has raised five life science-focused venture funds its flagship Venture Capital business unit and is currently investing out of its fifth fund. In addition, the firm recently closed on a new fund that is investing in companies domiciled in Singapore, Hong Kong and China. The firm generally looks to support companies with lead assets that can reach high value inflection points in 3-4 years and will consider opportunities in US, Canada, Europe, Singapore, Hong Kong and China.

The firm is currently seeking companies developing therapeutics or medical technologies to treat true unmet medical needs. The firm is therapeutic area agnostic, although the firm has historically been most active in immunology, oncology, and rare diseases. The firm typically prefers to invest in Series A/B rounds with a preference for lead assets between 18 months pre-IND and Phase 2a. Within devices, the firm generally prefers to invest in later stage opportunities, particularly those devices that have received market approval with early revenue.

The firm does not have any specific requirements for a firm’s management team. The firm is an active investor and seeks a director or observer position on a company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A seed fund focuses on applied AI technologies, and invests in three verticals: Digital Health, Enterprise and Automation. Within Digital Health, the firm invests in companies developing AI/ML, software-based technologies in the sectors of digital health, diagnostics and R&D services. The firm will invest $250K-500K in seed-stage companies based in the US and Canada, and will consider all companies, as long as they have a good business model.

Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will consider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery.

The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.